AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23432610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir with rifampicin in children
Number of subjects: 95
Study 23432610 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir without rifampicin in children
Number of subjects: 95
Study 23432610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin effect on lopinavir and ritonavir
Number of subjects: 95
Study 20874823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 0
Study 18676982 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prenatal protein-energy supplementation (protein-energy biscuits during pregnancy)
Number of subjects: 1267
Study 18676982 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers consumed the same supplement post-partum)
Number of subjects: 1267
Study 17179251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1.2 g p.o. before surgery
Number of subjects: 40
Study 17179251 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules 1 h before surgery
Number of subjects: 40
Study 14995937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 50
Study 14995937 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 50
Study 11176769 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physicians without advance directives (ADs)
Number of subjects: 82
Study 11176769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based physicians without advance directives (ADs)
Number of subjects: 82
Study 11176769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based physicians with scenario-based advance directives (ADs)
Number of subjects: 82
Study 11176769 — intervention group
Group type: COMPARATOR
Intervention: Family surrogates
Number of subjects: 82
Study 8940976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg single dose)
Number of subjects: 301
Study 8940976 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for three days)
Number of subjects: 301
Study 8940976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 301
Study 8940976 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 301
Study 1581275 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgicraft‐Copeland (clip)
Number of subjects: 780
Study 1581275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hewlett‐Packard (double‐helix spiral)
Number of subjects: 780
Study 1581275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocket‐Rolon (double‐helix spiral)
Number of subjects: 780
Study 3890391 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 10
Study 3890391 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine
Number of subjects: 10
Study 30811371 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 4092
Study 30811371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 4092
Study 30811371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Patch (NRT)
Number of subjects: 4092
Study 30811371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4092
Study 30811371 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 4092
Study 29215395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.05% as adjuvant therapy to corticosteroids
Number of subjects: 31
Study 29215395 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment only
Number of subjects: 31
Study 26428281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0μg/kg (PHE1 Group)
Number of subjects: 184
Study 26428281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.5μg/kg (PHE1.5 Group)
Number of subjects: 184
Study 26428281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.0μg/kg (PHE2 Group)
Number of subjects: 184
Study 26428281 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 2mL (Control Group)
Number of subjects: 184
Study 25054483 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (medium LiteTouch facemask)
Number of subjects: 12
Study 25054483 — intervention group
Group type: COMPARATOR
Intervention: Spacer mouthpiece
Number of subjects: 12
Study 22550054 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (traditional risk factors)
Number of subjects: 1790
Study 22550054 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (traditional + socioeconomic and less traditional risk factors)
Number of subjects: 1790
Study 22550054 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham heart risk score
Number of subjects: 1790
Study 22550054 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAS global vascular risk score
Number of subjects: 1790
Study 19090594 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetting alarm diaper training (n = 27)
Number of subjects: 39
Study 19090594 — intervention group
Group type: COMPARATOR
Intervention: Placebo alarm (control group, n = 12)
Number of subjects: 39
Study 17983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 64
Study 17983362 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 64
Study 15987331 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo HAART regimen
Number of subjects: 23
Study 15987331 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 students)
Number of subjects: 23
Study 11914253 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued statin therapy
Number of subjects: 1616
Study 11914253 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued statin therapy after hospitalization
Number of subjects: 1616
Study 11914253 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 1616
Study 10321141 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction
Number of subjects: 148
Study 10321141 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction
Number of subjects: 148
Study 10321141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive orthognathic surgery
Number of subjects: 148
Study 7660234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomenclature I (normal, bulge, herniation)
Number of subjects: 125
Study 7660234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomenclature II (normal, bulge, protrusion, extrusion)
Number of subjects: 125
Study 7660234 — intervention group
Group type: COMPARATOR
Intervention: Nomenclature I and II
Number of subjects: 125
Study 2087275 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-T2 breast cancer with node metastasis
Number of subjects: 40
Study 2087275 — intervention group
Group type: COMPARATOR
Intervention: T1-T2 breast cancer without node metastasis
Number of subjects: 40
Study 373705 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PEEP (5 cm H2O)
Number of subjects: 79
Study 373705 — intervention group
Group type: COMPARATOR
Intervention: Late PEEP (PEEP only when severe hypoxemia developed)
Number of subjects: 79
Study 30977312 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided antibiotic discontinuation
Number of subjects: 52
Study 30977312 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 52
Study 30977312 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided therapy
Number of subjects: 52
Study 28600696 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 (maintenance group)
Number of subjects: 87
Study 28600696 — intervention group
Group type: COMPARATOR
Intervention: CT-P10 (switch group)
Number of subjects: 87
Study 28600696 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 (both groups)
Number of subjects: 87
Study 25498732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg per day
Number of subjects: 174
Study 25498732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 23735181 — intervention group
Group type: COMPARATOR
Intervention: SB‐705498 12 mg alone
Number of subjects: 70
Study 23735181 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐705498 12 mg plus fluticasone propionate 200 μg (FP)
Number of subjects: 70
Study 23735181 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 200 μg (FP) alone
Number of subjects: 70
Study 23735181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21045074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine (high dose)
Number of subjects: 51
Study 21045074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine (low dose)
Number of subjects: 51
Study 21045074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19298291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) scaffolds
Number of subjects: 12
Study 19298291 — intervention group
Group type: COMPARATOR
Intervention: Zirconia (ZrO(2)) scaffolds
Number of subjects: 12
Study 17976289 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment provided by a nurse, consisting of four to six treatment sessions.
Number of subjects: 0
Study 17976289 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the GP (Control group).
Number of subjects: 0
Study 17976289 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment for a sub-group of patients with more severe pathology.
Number of subjects: 0
Study 15502727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus calcitriol
Number of subjects: 64
Study 15502727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15502727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 64
Study 15502727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 64
Study 11903206 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative practice model intervention (Bipolar Disorders Program - BDP)
Number of subjects: 0
Study 11903206 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9470805 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (up to 12 courses)
Number of subjects: 0
Study 9470805 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (6 courses)
Number of subjects: 0
Study 7943220 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (402 +/‐ 18 pM)
Number of subjects: 10
Study 7943220 — intervention group
Group type: COMPARATOR
Intervention: Low-dose insulin infusion (132 +/‐ 6 pM)
Number of subjects: 10
Study 3349551 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia combined with light general anaesthesia and postoperative pain relief with intermittent doses of bupivacaine
Number of subjects: 13
Study 3349551 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with non-narcotic analgesics
Number of subjects: 13
Study 29327828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching with vibration (VIB) - frequency of 30 Hz and 2 mm amplitude
Number of subjects: 27
Study 29327828 — intervention group
Group type: COMPARATOR
Intervention: Stretching without vibration (NoVIB)
Number of subjects: 27
Study 29327828 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VIB and NoVIB conditions
Number of subjects: 27
Study 28615017 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent medical evaluation
Number of subjects: 3800
Study 28615017 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 3800
Study 25823958 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 10 mg/kg IV (baseline, weeks 2 and 4)
Number of subjects: 43
Study 25823958 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg SC (baseline, week 4)
Number of subjects: 43
Study 25823958 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 10 mg/kg IV
Number of subjects: 43
Study 25823958 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg SC
Number of subjects: 43
Study 24351993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program (laughter therapy, exercise, foot care, education), provided once a week for 8 weeks, each session lasting 80 minutes
Number of subjects: 60
Study 24351993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program (laughter therapy, exercise, foot care, education)
Number of subjects: 60
Study 20428997 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS graft
Number of subjects: 56
Study 20428997 — intervention group
Group type: COMPARATOR
Intervention: Traditional colporrhaphy (TC)
Number of subjects: 56
Study 19037029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 4-6 hours until 37 weeks of gestation)
Number of subjects: 71
Study 19037029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing)
Number of subjects: 71
Study 19037029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 71
Study 19037029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 15995846 — intervention group
Group type: EXPERIMENTAL
Intervention: Healed ulcer
Number of subjects: 294
Study 15995846 — intervention group
Group type: COMPARATOR
Intervention: Non-healed ulcer
Number of subjects: 294
Study 15995846 — intervention group
Group type: COMPARATOR
Intervention: Caregivers of patients with a persisting ulcer
Number of subjects: 294
Study 12505741 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who indicated they were likely to administer CPR
Number of subjects: 4480
Study 12505741 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents with various characteristics (males, married, in paid employment, smokers, recently trained in CPR, prospective organ donors, those citing no barriers)
Number of subjects: 4480
Study 12505741 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who knew the victim or believed the victim would die without CPR
Number of subjects: 4480
Study 10456585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation after 5 weeks of abstinence (T2)
Number of subjects: 49
Study 10456585 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 49
Study 8984034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of solutions containing 12 to 36% of calories as protein, 24 to 48% as fat, and 40 to 64% as carbohydrate at 40, 90, or 160 kcal/h for 300 minutes.
Number of subjects: 26
Study 8984034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of sodium chloride (9 g/l) added to 16 infusates; osmolality of other 10 infusates was 24 to 98 mOsm.
Number of subjects: 26
Study 8984034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions at 40 and 90 kcal/h.
Number of subjects: 26
Study 2052894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate and 0.04% NaF rinsing solution (CXF)
Number of subjects: 243
Study 2052894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate and 500 ppm Sr (CXFS)
Number of subjects: 243
Study 2052894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate (CX)
Number of subjects: 243
Study 2052894 — intervention group
Group type: COMPARATOR
Intervention: Basic control group (C)
Number of subjects: 243
Study 6356732 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole plus local ampicillin
Number of subjects: 90
Study 6356732 — intervention group
Group type: COMPARATOR
Intervention: Local ampicillin
Number of subjects: 90
Study 31322058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to positive stereotypes of feminists
Number of subjects: 312
Study 31322058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to negative stereotypes of feminists
Number of subjects: 312
Study 31322058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exposure to stereotypes)
Number of subjects: 312
Study 30841655 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of policosanol
Number of subjects: 84
Study 30841655 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of policosanol
Number of subjects: 84
Study 30841655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 28278070 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression + kinesiotherapy (EC)
Number of subjects: 20
Study 28278070 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional compressive bandaging + kinesiotherapy (FCB)
Number of subjects: 20
Study 28278070 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy
Number of subjects: 20
Study 27079932 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA84 (20μg with Alum, 75μg with or without Alum, 200μg with or without Alum)
Number of subjects: 141
Study 27079932 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA84 (75μg with or without Alum, 200μg with or without Alum)
Number of subjects: 141
Study 27079932 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA84
Number of subjects: 141
Study 24714795 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical training (AFT) for 12 weeks, supervised, in cycle ergometer
Number of subjects: 21
Study 24714795 — intervention group
Group type: COMPARATOR
Intervention: Control procedure consisting of 15 minutes of stretching and 15 minutes of light walk
Number of subjects: 21
Study 21703900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg monthly (Group A - standard of care)
Number of subjects: 596
Study 21703900 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate 150 mg monthly with CTX feedback (Group B)
Number of subjects: 596
Study 20215905 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 3491
Study 20215905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491
Study 17593902 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load (HG) diet
Number of subjects: 32
Study 17593902 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic load (LG) diet
Number of subjects: 32
Study 17593902 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER)
Number of subjects: 32
Study 17593902 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 32
Study 16264388 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 73
Study 16264388 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 73
Study 12062320 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg im T enanthate weekly for 8 weeks (eugonadal group)
Number of subjects: 38
Study 12062320 — intervention group
Group type: COMPARATOR
Intervention: 200 mg im sodium chloride weekly for 8 weeks (eugonadal control group)
Number of subjects: 38
Study 12062320 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg im T enanthate biweekly for 8 weeks (hypogonadal group)
Number of subjects: 38
Study 11263171 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom
Number of subjects: 603
Study 11263171 — intervention group
Group type: COMPARATOR
Intervention: Condom
Number of subjects: 603
Study 7878170 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional deviant (change in both frequency and location) in the ignore condition
Number of subjects: 0
Study 7878170 — intervention group
Group type: COMPARATOR
Intervention: One-dimensional deviants (one frequency and one location deviant) in the ignore condition
Number of subjects: 0
Study 7878170 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend condition (discriminating deviants from standards)
Number of subjects: 0
Study 2298965 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA-UVB radiation (UVAB)
Number of subjects: 30
Study 2298965 — intervention group
Group type: COMPARATOR
Intervention: UVB
Number of subjects: 30
Study 109199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 109199 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 0
Study 31029921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and low-carbohydrate diet (HP)
Number of subjects: 270
Study 31029921 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (S)
Number of subjects: 270
Study 31029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 270
Study 28755394 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 308
Study 28755394 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 308
Study 28755394 — intervention group
Group type: COMPARATOR
Intervention: adalimumab/ABP 501
Number of subjects: 308
Study 26537940 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group (substituted water for DBs)
Number of subjects: 89
Study 26537940 — intervention group
Group type: COMPARATOR
Intervention: DB group (continued drinking DBs)
Number of subjects: 89
Study 23225065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser (1,342 nm) at low radiant exposure (2.8 J/cm²)
Number of subjects: 4
Study 23225065 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser (1,064 nm)
Number of subjects: 4
Study 23225065 — intervention group
Group type: COMPARATOR
Intervention: KTP laser (532 nm)
Number of subjects: 4
Study 23225065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser (1,342 nm)
Number of subjects: 4
Study 20926956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse width of 0.3 milliseconds
Number of subjects: 0
Study 20926956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse width of 1.5 milliseconds
Number of subjects: 0
Study 20926956 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement
Number of subjects: 0
Study 20926956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electrode placement
Number of subjects: 0
Study 19565809 — intervention group
Group type: EXPERIMENTAL
Intervention: Roncoleukin (intravenously) in Subgroup 1a (20 patients)
Number of subjects: 78
Study 19565809 — intervention group
Group type: EXPERIMENTAL
Intervention: Roncoleukin (indirect lymphotropic) in Subgroup 1b (30 patients)
Number of subjects: 78
Study 19565809 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments in Group 2 (28 patients)
Number of subjects: 78